SCHEMBL2857583

SCHEMBL2857583

Cc1ccc(O)cc1-n1nc2c(c1N)c(=O)[nH]c1ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.43
CHEK1 O14757 1/20 0.43
PKMYT1 Q99640 4/20 0.39
EPHB3 P54753 2/20 0.39
EPHA3 P29320 1/20 0.39
WEE1 P30291 1/20 0.39
EPHB4 P54760 1/20 0.39
CREBBP Q92793 1/20 0.39
TDP2 O95551 1/20 0.39
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
KDR P35968 1/20 0.39
DAO P14920 2/20 0.39
DDO Q99489 2/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
CASP6 P55212 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2859059 0.89 ADORA3 (0.45) ADORA3CHEK1PDGFRBFGFR1KDR
SCHEMBL2860183 0.87 FGFR1 (0.46) ADORA3CHEK1TDP2FGFR1KDR
SCHEMBL2868746 0.87 CHEK1 (0.45) ADORA3CHEK1TDP2PDGFRBFGFR1
SCHEMBL2868559 0.85 ADORA3 (0.47) ADORA3CHEK1EPHB4MEN1KMT2A
SCHEMBL2864971 0.84 CHEK1 (0.45) CHEK1FGFR1KDRGAA
SCHEMBL2857838 0.84 PARP1 (0.39) CHEK1PKMYT1TDP2PDGFRBFGFR1
SCHEMBL2868654 0.84 CHEK1 (0.40) ADORA3CHEK1TDP2PDGFRBFGFR1
SCHEMBL2881305 0.84 KDM4E (0.43) ADORA3CHEK1TDP2DAODDO
SCHEMBL2860224 0.83 RET (0.39) PKMYT1KDRMEN1GAAKMT2A
SCHEMBL2863002 0.83 KDM4E (0.39) ADORA3EPHB4MEN1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US claimed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP claimed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 ADORA3 1829/4885CHEK1 605/4885PKMYT1 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.